ArticleEmerging microbes & infections2022
Emerging and re-emerging KPC-producing hypervirulent
Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Prioritization of Critical Factors for Surveillance of the Dissemination of Antibiotic Resistance inInternational journal of molecular sciences · 2023Pooled it
- Emergence of ceftazidime-avibactam resistance mediated by KPC variants KPC-71 and KPC-78 in ST463Microbiology spectrum · 2026Article
- Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Enhanced Spread of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Molecular epidemiological association between antimicrobial resistance characteristics and type III secretion system in carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Molecular insights into the persistence and co-occurrence of two different carbapenem-resistantMicrobiology spectrum · 2025Article
- Carbapenem-resistantFrontiers in pharmacology · 2025Article
- A retrospective study of the antimicrobial susceptibility patterns ofFrontiers in microbiology · 2025Article
- Glutamine potentiates cefoperazone-sulbactam activity againstFrontiers in microbiology · 2025Article
- Environmental Persistence of High-Risk KPC-Producing ST463Infection and drug resistance · 2025Article
- Characterization of genetic context ofFrontiers in microbiology · 2025Article
- ESKAPE in China: epidemiology and characteristics of antibiotic resistance.Emerging microbes & infections · 2024Review
- Molecular characterization of extensively drug-resistant hypervirulent Pseudomonas aeruginosa isolates in China.Annals of clinical microbiology and antimicrobials · 2024Article
- Phenotypic and genomic characterization ofMicrobial genomics · 2023Article
- RVFScan predicts virulence factor genes and hypervirulence of the clinical metagenome.Briefings in bioinformatics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.